Trial Profile

AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children (ARTEMIS)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AR 101 (Primary)
Indications Peanut hypersensitivity
Focus Registrational; Therapeutic Use
Acronyms ARTEMIS
Sponsors Aimmune Therapeutics

Most Recent Events

30 Jun 2022 Results published in the Aimmune Therapeutics Media Release.
30 Jun 2022 According to an Aimmune Therapeutics media release, results from an analysis to be presented on health-related quality of life (HRQoL) among patients from the Phase 3 PALISADE, ARC004 (PALISADE follow-on), ARTEMIS, RAMSES and ARC011 (RAMSES follow-on) trials will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress.
16 Feb 2022 Results published in an Aimmune Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com